First AD

Second AD

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

Data for Navtemadlin in Relapsed/Refractory Myelofibrosis

Myeloproliferative Neoplasms

INC-22-OSD1258 - /clinical/myeloproliferative-neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Developments in the Management of Myelofibrosis After ASH 2024

OncLive News Network®

Sylvester Comprehensive Cancer Center, University of Miami

Cancer Centers

Partner

Treatment Trends: JAK Inhibitor Selection in Myelofibrosis

Challenges With Low-Dose Ruxolitinib in Myelofibrosis

The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis

PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis

Other Notable Myelofibrosis Data From ASH 2024